Literature DB >> 11713228

Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor.

F Dif1, E Saunier, B Demeneix, P A Kelly, M Edery.   

Abstract

Inhibition of PRL hormone signaling by suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2-containing protein (CIS) was investigated in transfected HEK 293 cells. We used the physiologically relevant wild-type beta-casein promoter as a target gene for PRL action. We demonstrate that CIS produces a 70% inhibition of PRL signaling by a mechanism distinct from, and downstream of, the effect of SOCS-1 on JAK2. This inhibition involves association with the PRL receptor (PRLR), resulting in the inhibition of signal transducer and activator of transcription 5 (STAT5) activation. Further, we show that SOCS-3 coimmunoprecipitates with the PRLR. These data suggest that SOCS-3 involves a second pathway for the inhibition of PRL signaling other than JAK2 inhibition. Additional results indicate that SOCS-2 can play a more important potentiator role on PRL signaling, resulting in a restoration of 50% of transcriptional inhibition induced by SOCS-3 and a restoration of 100% of transcriptional inhibition induced by CIS. SOCS-2 was able to block the inhibitory effect of SOCS-1. These results indicate that SOCS-2 seems to be an antagonist of the other SOCS. SOCS-1 binds JAK2 and inhibits its phosphorylation; SOCS-3 does not bind JAK2 but binds the PRLR that may mediate its inhibition of JAK2; and finally, CIS binds the PRLR but inhibits signal transducer and activator of transcription 5 rather than JAK2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713228     DOI: 10.1210/endo.142.12.8549

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Effect of suppressor of cytokine signaling 2 (SOCS2) on fat metabolism induced by growth hormone (GH) in porcine primary adipocyte.

Authors:  Hai Li Yang; Chan Sun; Chao Sun; Ren Li Qi
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 3.  Suppression of cytokine signaling: the SOCS perspective.

Authors:  Edmond M Linossi; Jeffrey J Babon; Douglas J Hilton; Sandra E Nicholson
Journal:  Cytokine Growth Factor Rev       Date:  2013-03-30       Impact factor: 7.638

4.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

5.  PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin.

Authors:  Jing Tao; Peter Oladimeji; Leah Rider; Maria Diakonova
Journal:  Mol Endocrinol       Date:  2011-06-30

6.  Regulation of cytokine-inducible SH2-containing protein (CIS) by ubiquitination and Elongin B/C interaction.

Authors:  Philip J Jensik; Lydia A Arbogast
Journal:  Mol Cell Endocrinol       Date:  2014-11-04       Impact factor: 4.102

7.  SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation.

Authors:  Gillian M Tannahill; Joanne Elliott; Anna C Barry; Linda Hibbert; Nicolas A Cacalano; James A Johnston
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

8.  Leptin signaling: A key pathway in immune responses.

Authors:  Claudio Procaccini; Elaine V Lourenco; Giuseppe Matarese; Antonio La Cava
Journal:  Curr Signal Transduct Ther       Date:  2009-01-01

Review 9.  Regulation of prolactin receptor levels and activity in breast cancer.

Authors:  G Swaminathan; B Varghese; S Y Fuchs
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

10.  Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune system.

Authors:  Adrian Erlebacher; Dorothy Zhang; Albert F Parlow; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.